Literature DB >> 8355065

Impact of antianginal medications, peak heart rate and stress level on the prognostic value of a normal exercise myocardial perfusion imaging study.

K A Brown1, M Rowen.   

Abstract

We sought to determine whether antianginal medications or the level of achieved stress affect the prognostic value of a normal exercise 201Tl study. We studied 261 patients with a normal exercise 201Tl study for 23 +/- 6 mo. Antianginal medications were taken at the time of stress testing in 128 patients. Peak heart rate ranged from 82 to 217 bpm; percent maximal predicted heart rate ranged from 42% to 136%. Chi-square analysis was used to determine the relationship of cardiac events to antianginal medications and stress indices. Primary cardiac events were defined as cardiac death or nonfatal myocardial infarction. Primary cardiac events occurred in six patients yielding an annual incidence of 1.2% per year. There was no significant relationship between cardiac event rate and antianginal medication use or any stress index, including Bruce stage, peak heart rate or blood pressure or percent maximal predicted heart rate achieved. The risk of cardiac death or nonfatal myocardial infarction in patients with a normal exercise 201Tl is low and is not affected by concurrent antianginal treatment or degree of stress achieved.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8355065

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

1.  Safety and feasibility of atropine added to submaximal exercise stress testing with Tl-201 SPECT for the diagnosis of myocardial ischemia.

Authors:  Juan Cosín-Sales; Alicia M Maceira; María J García-Velloso; Alfonso Macías; Marta Gimenez; Ignacio García-Bolao; Isabel Coma-Canella
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

2.  Antianginal medications and diagnostic accuracy of myocardial perfusion imaging.

Authors:  Nikant Kumar Sabharwal; Avijit Lahiri
Journal:  J Nucl Cardiol       Date:  2003 Jul-Aug       Impact factor: 5.952

3.  Patient preparation for nuclear imaging: when should anti-ischemic medications be withheld?

Authors:  Sarkis B Baghdasarian; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2007 Nov-Dec       Impact factor: 5.952

4.  Symptom-limited exercise combined with dipyridamole stress: prognostic value in assessment of known or suspected coronary artery disease by use of gated SPECT imaging.

Authors:  Alan W Ahlberg; Sarkis B Baghdasarian; Haris Athar; Jeffrey P Thompsen; Deborah M Katten; Gavin L Noble; Igor Mamkin; Anuj R Shah; Ivette A Leka; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2008 Jan-Feb       Impact factor: 5.952

5.  Influence of cardiac stress protocol on myocardial perfusion imaging accuracy: The role of exercise level on the evaluation of ischemic burden.

Authors:  Alessia Gimelli; Riccardo Liga; Emilio Maria Pasanisi; Mirta Casagranda; Michele Coceani; Paolo Marzullo
Journal:  J Nucl Cardiol       Date:  2015-03-27       Impact factor: 5.952

6.  Stress protocol and accuracy of myocardial perfusion imaging: Is it better to start from the end?

Authors:  Marco Spadafora; Marco Salvatore; Alberto Cuocolo
Journal:  J Nucl Cardiol       Date:  2015-04-01       Impact factor: 5.952

Review 7.  Prognostic value of myocardial perfusion imaging: state of the art and new developments.

Authors:  K A Brown
Journal:  J Nucl Cardiol       Date:  1996 Nov-Dec       Impact factor: 5.952

8.  Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial.

Authors:  M I Ross; E Wu; J T Wilkins; D Gupta; S Shen; D Aulwes; K Montero; T A Holly
Journal:  J Nucl Cardiol       Date:  2013-02-13       Impact factor: 5.952

9.  The impact of adjunctive adenosine infusion during exercise myocardial perfusion imaging: Results of the Both Exercise and Adenosine Stress Test (BEAST) trial.

Authors:  Thomas A Holly; Aaron Satran; David S Bromet; Jennifer H Mieres; Martin J Frey; Michael D Elliott; Gary V Heller; Robert C Hendel
Journal:  J Nucl Cardiol       Date:  2003 May-Jun       Impact factor: 5.952

10.  Safety and feasibility of atropine added in patients with sub-maximal heart rate during exercise myocardial perfusion SPECT.

Authors:  Filippo Maria Sarullo; Corrado Ventimiglia; Andrea Taormina; Vincenzo Azzarello; Filippo Felice; Annamaria Martino; Salvatore Paterna; Pietro Di Pasquale
Journal:  Int J Cardiovasc Imaging       Date:  2006-11-16       Impact factor: 2.316

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.